A case of relapsed-refractory AML

Authors: Dr. Anath Lionel and Dr. Joanne Britto, McMaster University

Reviewer: Dr. Hassan Sibai, Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Learning Objectives:

As the end of this self-assessment module, participants should be able to:

1. Describe approved treatment options for patients with relapsed or refractory FLT3 positive acute myeloid leukemia.
2. Define the mechanism of action and clinical efficacy for an approved agent for relapsed/refractory acute myeloid
   leukemia.
3. Describe the safety data and common adverse events associated with targeted FLT3 inhibitor therapy.

CHS Scientific Planning Committee Members (2022)

Dr. Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None